Ozempic semaglutide

The #1 adherence lever for Ozempic is not efficacy — it's surviving the first 4–8 weeks of GI side effects; patients who receive a peer-validated "this gets better" message before dose escalation are the ones still on therapy at month 6.

• Ozempic's most celebrated effect is silencing 'food noise' — patients describe it as a neurological shift, not willpower, making this the single most powerful emotional differentiator from prior weight-loss attempts.
• GI side effects (nausea, vomiting, sulfur burps, dehydration) dominate the initiation window and are the primary driver of early discontinuation, yet most patients report significant improvement by weeks 6–12 if they survive dose escalation.
• Cost and insurance access create a two-tier patient experience: commercially insured T2D patients often pay as little as $25/month, while off-label weight-loss patients without Wegovy coverage face $900–$1,350 cash prices and frequently turn to compounded semaglutide.
• The 'weight rebound after stopping' narrative is a growing adherence threat — patients who quit without a maintenance plan report rapid regain and psychological distress, representing an urgent gap in offboarding support.